Engineered immune cells take on Hard-to-Treat kidney cancer
NCT ID NCT07645690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of immune cell therapy called CLEAR CAR-T (ET-970) in 30 people with advanced clear cell kidney cancer that has not responded to at least two prior treatments. The therapy uses donor immune cells engineered to target a protein called CD70 on cancer cells. The main goals are to check safety and see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLEAR CAR-T cell injection (ET-970) - an engineered immune cell therapy targeting CD70
What this could lead to
If it works, this could point toward a new treatment option for advanced kidney cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, small trial (30 people) focused on safety. The therapy may not shrink tumors or could cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, China
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Urology Department of Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••